Human-Based Dilated Cardiomyopathy Model (LMNA)
The Challenge
Genetically driven cardiomyopathies like LMNA-associated DCM represent a high-risk patient population with early-onset electrical instability and progressive contractile failure. Yet current in vitro models often fail to capture the slow-developing, structurally complex nature of chronic cardiomyopathy. This limits their utility for drug screening, disease modeling, or therapeutic validation in genetically defined contexts.
Our Solution
We offer a chronic DCM assay using hiPSC-derived cardiomyocytes harboring an LMNA mutation known to cause familial DCM. The model displays hallmark features such as reduced contractile amplitude and rhythm irregularities over time. Ideal for testing chronic drug exposure or genetic modifiers, this system allows compound evaluation under disease-relevant conditions. Our platform supports functional, temporal, and morphodynamic profiling, enabling deeper insight into compound behavior in a clinically meaningful DCM background.